
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher Corporation has demonstrated a positive financial outlook, highlighted by an increase in performance obligations, which rose to $4.9 billion in 2Q25 from $4.5 billion in 1Q25. The company's life sciences sector is anticipated to achieve a growth ramp of approximately 4.5% in 4Q25, driven by favorable comparisons in genomics, improved performance in China, and new product launches. Additionally, the Cepheid respiratory segment is expected to perform robustly in the upcoming quarters, projecting revenues of $300-350 million in 3Q25 and $450-500 million in 4Q25, indicating a solid demand trajectory.
Bears say
The financial outlook for Danaher appears negative due to a decline in the percentage of 2Q25 obligations expected to be recognized as revenue within the next 12 months, dropping from 48% to 46%. Additionally, there are significant risks associated with geopolitical disruptions, foreign exchange volatility, and the failure of high-growth end-markets, particularly in China, to recover. Furthermore, the company's recent revenue guidance for the Biotechnology and Life Sciences sector fell below expectations for 3Q25, suggesting underlying challenges that may impact future performance.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares